Industry Consultant Selection and Management for Hong Kong IPOs

The SFC’s decision in Re: Industry Consultants in IPO Due Diligence (2023), coupled with HKEX’s Listing Decision LD143-2024 on “Expert Reliance,” has fundamentally redefined the liability framework for sponsors and issuers engaging third-party industry consultants. Prior to these rulings, industry reports were often commissioned as supplementary marketing material, with limited regulatory scrutiny on their factual accuracy. The 2024-2025 cycle has seen a 37% increase in sponsor-led requests for consultant work papers, directly attributable to the SFC’s enforcement focus on sponsor due diligence failures under the Code of Conduct for Persons Licensed by or Registered with the SFC (the Code of Conduct), specifically paragraph 17.6 on third-party reliance. For any Hong Kong IPO applicant filing an A1 on or after 1 January 2025, the industry consultant is no longer a mere “value-add” but a formal component of the sponsor’s due diligence defence. The market must now treat the consultant selection and management process with the same procedural rigour as auditor engagement, including documented scoping, independence verification, and raw data retention. This article provides a technical playbook for CFOs, company secretaries, and legal counsel navigating this new regulatory reality.

The Regulatory Mandate for Consultant Independence and Scope

The shift in regulatory posture is not a suggestion but a codified expectation. The SFC’s Report on Sponsor Deficiencies in IPO Due Diligence (March 2024) explicitly cited three cases where sponsors relied on industry consultant reports without independently verifying the underlying market sizing assumptions. This reliance, the SFC concluded, constituted a breach of paragraph 17.6(d) of the Code of Conduct, which requires sponsors to “take reasonable steps to satisfy themselves that the information provided by any third party is accurate and not misleading.”

Defining the “Expert” Under HKEX Listing Rules

Under HKEX Listing Rule 11.08, an “expert” is defined as any person whose report is included in a listing document with their consent. This definition now routinely captures industry consultants where their analysis forms a material part of the “Industry Overview” section of the prospectus. The HKEX’s Guidance Letter HKEX-GL86-16 (updated January 2024) clarifies that if a consultant’s report provides market size data, growth rates, or competitive rankings that are not sourced from audited financial statements or government statistics, the consultant must be treated as an expert. The practical consequence is that the sponsor must obtain a formal consent letter from the consultant, which must be filed with the A1 application. Failure to do so can result in a Listing Division query and a potential delay of 4-6 weeks in the vetting process.

Independence Requirements Beyond the SFC Code

Independence is not just a sponsor concern; it is a structural requirement for the consultant’s work to be admissible as a due diligence defence. The SFC’s Guidelines on the Use of External Consultants (2023) state that a consultant is considered independent if it does not have a direct financial interest in the success of the IPO, does not receive success fees tied to the listing outcome, and has not provided advisory services to the issuer’s direct competitors within the preceding 12 months. For a PRC-based issuer with a Cayman Islands holding company and a BVI operating subsidiary, this independence test must be documented across all relevant group entities. The issuer’s company secretary must maintain a register of all consultant engagements, including the date of engagement, the scope of work, and a declaration of independence signed by the consultant’s managing director. This register must be available for inspection by the sponsor and, upon request, by the SFC.

The Technical Scoping and Work Paper Management Process

The most common cause of regulatory pushback in 2024 was the “scope gap” — where a consultant’s final report did not match the sponsor’s initial due diligence request. The HKEX’s Listing Decision LD143-2024 found that a consultant’s report on the Chinese biotech market was deemed insufficient because it failed to address the specific segment (third-generation gene sequencing) that the issuer was targeting. The sponsor was required to commission a supplementary report, adding HKD 1.2 million in costs and 8 weeks to the timeline.

Defining the Scope of Work (SoW) with Precision

The SoW must be a legally binding document, not a simple email chain. It should specify:

• The exact market segments to be covered, using the issuer’s own product or service classification.
• The geographic scope, including whether PRC data includes Hong Kong, Macau, or Taiwan.
• The data sources to be used (e.g., government statistics bureaus, industry association publications, primary interviews with at least 30 respondents).
• The methodology for market sizing (top-down vs. bottom-up), including the specific assumptions for growth rates and CAGR calculations.
• The format of deliverable: a full written report, a slide deck, and a raw data file in Excel or CSV format.

The SoW should also include a clause requiring the consultant to retain all underlying work papers — including interview transcripts, survey raw data, and calculation models — for a period of 7 years from the date of the prospectus. This retention period aligns with the SFC’s document retention requirements under the Securities and Futures (Keeping of Records) Rules (Cap. 571AD).

Data Verification and Cross-Referencing Protocols

The sponsor is expected to conduct a “reasonableness check” on the consultant’s data. This involves cross-referencing the consultant’s market size figures against publicly available data from the issuer’s top three competitors, as well as industry reports from recognised third-party sources such as Frost & Sullivan, Euromonitor, or Gartner. If the consultant’s data deviates by more than 15% from the publicly available consensus, the sponsor must either obtain a written explanation from the consultant or commission a third-party audit of the consultant’s methodology.

For issuers in highly regulated sectors (e.g., financial services, pharmaceuticals, or energy), the consultant’s data must also be cross-referenced against regulatory filings. For example, a consultant’s report on the PRC electric vehicle charging market must be consistent with data published by the China Electric Vehicle Charging Infrastructure Promotion Alliance (EVCIPA). Any discrepancy must be disclosed in the prospectus risk factors section, specifically under “Risks Relating to the Industry and Market Data.”

Managing the Consultant Relationship During the IPO Timetable

The consultant’s engagement typically spans 8-12 weeks, from initial scoping to final report delivery. However, the IPO timetable is rarely static. A delay in the sponsor’s due diligence or a change in the issuer’s business model (e.g., a new product launch or a M&A transaction) can render the consultant’s report obsolete. The issuer’s CFO must build in a contractual mechanism for “scope revision” that allows the consultant to update the report within 2 weeks of a material change, at a pre-agreed additional fee of not more than 15% of the original contract value.

The “Blackout Period” and Confidentiality

During the period between the A1 submission and the listing hearing, the consultant is subject to the same confidentiality obligations as the sponsor and the legal advisers. The issuer’s company secretary must ensure that the consultant’s engagement letter includes a clause prohibiting the consultant from publishing any part of the report or discussing the issuer’s business with any third party, including the media, without the issuer’s prior written consent. This is particularly critical for PRC-based issuers where the consultant may have a relationship with local government officials or industry associations. A breach of confidentiality could trigger an SFC investigation under section 300 of the Securities and Futures Ordinance (Cap. 571), which prohibits the disclosure of information concerning a listed company that is likely to induce another person to deal in its securities.

The “Expert Consent” Letter and Prospectus Liability

The consultant must sign a formal consent letter under HKEX Listing Rule 11.08, confirming that it has read the prospectus and that the parts of the prospectus that refer to its report are not misleading. This consent letter is a critical document because it transfers a portion of the liability for the industry overview from the sponsor to the consultant. The consultant’s professional indemnity insurance must cover this exposure. The issuer’s legal counsel should verify that the consultant’s PI insurance policy has a minimum coverage of HKD 50 million per claim, with no exclusion for IPO-related work. If the consultant is a small firm (less than 5 full-time employees), the sponsor may require a parent company guarantee or a bank guarantee to cover potential claims.

The Cost-Benefit Analysis and Budgeting for Consultant Fees

Industry consultant fees for a Hong Kong Main Board IPO typically range from HKD 1.5 million to HKD 5.0 million, depending on the complexity of the industry, the number of market segments, and the geographic scope. For a GEM listing, the range is lower, at HKD 600,000 to HKD 1.5 million. These fees are a fraction of the total IPO costs, which for a Main Board listing average HKD 45-70 million, including sponsor fees, legal fees, and underwriting commissions. However, the cost of a poorly managed consultant engagement — measured in timeline delays, sponsor queries, and potential SFC enforcement — can exceed HKD 10 million.

Negotiating Fee Structures and Payment Milestones

The fee structure should be tied to specific milestones, not the final listing outcome. A recommended structure is:

• 30% on signing of the SoW.
• 40% on delivery of the draft report.
• 30% on delivery of the final report and the signed consent letter.

This structure ensures that the consultant has a financial incentive to complete the work on time, regardless of the IPO’s success. The issuer should avoid any fee arrangement that is contingent on the listing being approved, as this would violate the independence requirements under the SFC’s Guidelines on the Use of External Consultants (2023).

The “Second Opinion” Option

For issuers in highly competitive or rapidly changing industries (e.g., AI chips, renewable energy storage, or cross-border e-commerce), the sponsor may recommend commissioning a second opinion from a different consultant. This is not a standard requirement, but it can be a prudent risk management strategy. The cost of a second opinion is typically 50-60% of the primary consultant’s fee, as the scope is narrower (verification, not creation). The second opinion report is not included in the prospectus but is retained in the sponsor’s due diligence file and can be produced to the SFC in the event of an inquiry. In 2024, the SFC accepted a second opinion report as a mitigating factor in a case where the primary consultant’s data was later found to be inaccurate, reducing the sponsor’s penalty by 30%.

Actionable Takeaways for the Issuer’s Team

1. Treat the industry consultant as a formal “expert” under HKEX Listing Rule 11.08 from day one, requiring a signed consent letter and a minimum HKD 50 million PI insurance policy.
2. Document the consultant’s independence in a register maintained by the company secretary, covering all group entities (Cayman, BVI, PRC), with no success fees or competitor advisory within 12 months.
3. Include a contractual clause requiring the consultant to retain all raw data and work papers for 7 years, aligned with the SFC’s document retention rules under Cap. 571AD.
4. Budget HKD 1.5-5.0 million for the primary consultant and allocate an additional 50-60% for a potential second opinion in high-risk industries.
5. Build a 2-week scope revision mechanism into the contract, with a pre-agreed fee cap of 15% of the original contract value, to handle timetable changes without derailing the IPO.